Azurity Pharmaceuticals, Inc. v. Bionpharma Inc. > Documents

Date Field	Doc. No.	Description (Pages)
Mar 27, 2023	197	CONSOLIDATION ORDER: Azurity Pharmaceuticals, Inc. v. Novitium Pharma LLC, No. 23-cv-163, is CONSOLIDATED with Azurity Pharmaceuticals, Inc. v. Bionpharma Inc., Nos. 21-cv-1286 and 21-cv-1455, for discovery and trial. Bionpharma's Motion for Reconsideration (ECF No. 279 in 21-cv-1286 and ECF No. 183 in 21-cv-1455) is DENIED. (See Order for further details) Signed by Judge Mitchell S. Goldberg on 03/27/2023. (smg) (Entered: 03/28/2023) (11)
Mar 24, 2023	196	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding supplemental information - re (287 in 1:21-cv-01286-MSG, 191 in 1:21-cv-01455-MSG) Letter,. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 03/24/2023) (Main Document) (1)
Mar 24, 2023	196	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding supplemental information - re (287 in 1:21-cv-01286-MSG, 191 in 1:21-cv-01455-MSG) Letter,. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 03/24/2023) (Exhibit A) (3)
Mar 22, 2023	193	RESPONSE to Motion re 183 MOTION for Reconsideration re (172 in 1:21-cv-01455-MSG, 268 in 1:21-cv-01286-MSG) Scheduling Order,,, (264 in 1:21-cv-01286-MSG, 168 in 1:21-cv-01455-MSG) Statement, filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan) (Entered: 03/22/2023) (18)
Mar 22, 2023	194	DECLARATION re (193 in 1:21-cv-01455-MSG) Response to Motion, (289 in 1:21-cv-01286-MSG) Response to Motion, -- Declaration of Jeffrey C. Bank -- by Azurity Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 03/22/2023) (Main Document) (4)
Mar 22, 2023	195	NOTICE OF SERVICE of (1) Azurity's Objections to Biopharma's Fed. Rule Civ. P. 45 Subpoenas to Drs. Steven Little and Stephen Byrn; (2) Non-Party Dr. Steven Little's Responses and Objections to Biopharma' Fed. Rule Civ. P. 45 Subpoena; and (3) Non-Party Dr. Stephen R. Byrn's Responses and Objections to Biopharma's Fed. Rule Civ. P. 45 Subpoena filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 03/22/2023) (3)
Mar 22, 2023	194	DECLARATION re (193 in 1:21-cv-01455-MSG) Response to Motion, (289 in 1:21-cv-01286-MSG) Response to Motion, -- Declaration of Jeffrey C. Bank -- by Azurity Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 03/22/2023) (Exhibit A) (4)
Mar 17, 2023	192	NOTICE OF SERVICE of 1) Third Supplemental Initial Disclosures Pursuant to Rule 26(a)(1); (2) Sixth Set of Requests for Production to Bionpharma (Nos. 121-129); and (3) Fourth Supplemental Objections and Responses to Defendant Bionpharmas First Set of Interrogatories filed by Azurity Pharmaceuticals, Inc.(Dellinger, Megan) (Entered: 03/17/2023) (3)
Mar 15, 2023	191	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding Opposition to Bionpharma's Motion Requesting Leave to File for Summary Judgment - re (188 in 1:21-cv-01455-MSG, 284 in 1:21-cv-01286-MSG) Letter. (Dellinger, Megan) (Entered: 03/15/2023) (5)
Mar 14, 2023	190	NOTICE to Take Deposition of Plaintiff Azurity Pursuant to Fed. R. Civ. P. 30(b)(6) on May 5, 2023 filed by Bionpharma Inc..(Haney, Megan) (Entered: 03/14/2023) (23)
Mar 13, 2023	189	NOTICE OF SERVICE of Third Supplemental Objections and Responses to Defendant Bionpharma's First Set of Interrogatories filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 03/13/2023) (3)
Mar 8, 2023	183	MOTION for Reconsideration re (172 in 1:21-cv-01455-MSG, 268 in 1:21-cv-01286-MSG) Scheduling Order,,, (264 in 1:21-cv-01286-MSG, 168 in 1:21-cv-01455-MSG) Statement, - filed by Bionpharma Inc.. (Attachments: # 1 Proposed Order)(Phillips, John) (Entered: 03/08/2023) (Main Document) (3)
Mar 8, 2023	184	OPENING BRIEF in Support re 183 MOTION for Reconsideration re (172 in 1:21-cv-01455-MSG, 268 in 1:21-cv-01286-MSG) Scheduling Order,,, (264 in 1:21-cv-01286-MSG, 168 in 1:21-cv-01455-MSG) Statement, filed by Bionpharma Inc..Answering Brief/Response due date per Local Rules is 3/22/2023. (Phillips, John) (Entered: 03/08/2023) (17)
Mar 8, 2023	185	DECLARATION re (183 in 1:21-cv-01455-MSG, 279 in 1:21-cv-01286-MSG) MOTION for Reconsideration re (172 in 1:21-cv-01455-MSG, 268 in 1:21-cv-01286-MSG) Scheduling Order,,, (264 in 1:21-cv-01286-MSG, 168 in 1:21-cv-01455-MSG) Statement, , (184 in 1:21-cv-01455-MSG) Opening Brief in Support, (280 in 1:21-cv-01286-MSG) Opening Brief in Support, of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Phillips, John) (Entered: 03/08/2023) (Main Document) (2)
Mar 8, 2023	186	DECLARATION re (183 in 1:21-cv-01455-MSG, 279 in 1:21-cv-01286-MSG) MOTION for Reconsideration re (172 in 1:21-cv-01455-MSG, 268 in 1:21-cv-01286-MSG) Scheduling Order,,, (264 in 1:21-cv-01286-MSG, 168 in 1:21-cv-01455-MSG) Statement, , (184 in 1:21-cv-01455-MSG) Opening Brief in Support, (280 in 1:21-cv-01286-MSG) Opening Brief in Support, of Christopher J. Kelly by Bionpharma Inc.. (Phillips, John) (Entered: 03/08/2023) (5)
Mar 8, 2023	187	NOTICE OF SERVICE of Defendant Bionpharma's Subpoenas to Stephen R. Bryn and Steven Little filed by Bionpharma Inc..(Haney, Megan) (Entered: 03/08/2023) (2)
Mar 8, 2023	188	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Request for Leave to File for Summary Judgment Based on Collateral Estoppel. (Attachments: # 1 Proposed Order)(Phillips, John) (Entered: 03/08/2023) (Main Document) (5)
Mar 8, 2023	188	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Request for Leave to File for Summary Judgment Based on Collateral Estoppel. (Attachments: # 1 Proposed Order)(Phillips, John) (Entered: 03/08/2023) (Proposed Order) (1)
Mar 8, 2023	183	MOTION for Reconsideration re (172 in 1:21-cv-01455-MSG, 268 in 1:21-cv-01286-MSG) Scheduling Order,,, (264 in 1:21-cv-01286-MSG, 168 in 1:21-cv-01455-MSG) Statement, - filed by Bionpharma Inc.. (Attachments: # 1 Proposed Order)(Phillips, John) (Entered: 03/08/2023) (Proposed Order) (2)
Mar 8, 2023	185	DECLARATION re (183 in 1:21-cv-01455-MSG, 279 in 1:21-cv-01286-MSG) MOTION for Reconsideration re (172 in 1:21-cv-01455-MSG, 268 in 1:21-cv-01286-MSG) Scheduling Order,,, (264 in 1:21-cv-01286-MSG, 168 in 1:21-cv-01455-MSG) Statement, , (184 in 1:21-cv-01455-MSG) Opening Brief in Support, (280 in 1:21-cv-01286-MSG) Opening Brief in Support, of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Phillips, John) (Entered: 03/08/2023) (Exhibit A) (3)
Mar 8, 2023	185	DECLARATION re (183 in 1:21-cv-01455-MSG, 279 in 1:21-cv-01286-MSG) MOTION for Reconsideration re (172 in 1:21-cv-01455-MSG, 268 in 1:21-cv-01286-MSG) Scheduling Order,,, (264 in 1:21-cv-01286-MSG, 168 in 1:21-cv-01455-MSG) Statement, , (184 in 1:21-cv-01455-MSG) Opening Brief in Support, (280 in 1:21-cv-01286-MSG) Opening Brief in Support, of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Phillips, John) (Entered: 03/08/2023) (Exhibit B) (4)
Mar 8, 2023	185	DECLARATION re (183 in 1:21-cv-01455-MSG, 279 in 1:21-cv-01286-MSG) MOTION for Reconsideration re (172 in 1:21-cv-01455-MSG, 268 in 1:21-cv-01286-MSG) Scheduling Order,,, (264 in 1:21-cv-01286-MSG, 168 in 1:21-cv-01455-MSG) Statement, , (184 in 1:21-cv-01455-MSG) Opening Brief in Support, (280 in 1:21-cv-01286-MSG) Opening Brief in Support, of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Phillips, John) (Entered: 03/08/2023) (Exhibit C) (4)
Mar 3, 2023	182	NOTICE of Subpoenas by Bionpharma Inc. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Haney, Megan) (Entered: 03/03/2023) (Main Document) (1)
Mar 3, 2023	182	NOTICE of Subpoenas by Bionpharma Inc. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Haney, Megan) (Entered: 03/03/2023) (Exhibit 1) (13)
Mar 3, 2023	182	NOTICE of Subpoenas by Bionpharma Inc. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Haney, Megan) (Entered: 03/03/2023) (Exhibit 2) (13)
Mar 2, 2023	173	NOTICE to Take Deposition of Dave Ritchie Pursuant to Rule 30(b)(1) on June 6, 2023 filed by Bionpharma Inc..(Phillips, John) (Entered: 03/02/2023) (3)
Mar 2, 2023	174	NOTICE to Take Deposition of David W. Miles Pursuant to Rule 30(b)(1) on June 22, 2023 filed by Bionpharma Inc..(Phillips, John) (Entered: 03/02/2023) (3)
Mar 2, 2023	175	NOTICE to Take Deposition of Nailesh A. Bhatt Pursuant to Rule 30(b)(1) on May 9, 2023 filed by Bionpharma Inc..(Phillips, John) (Entered: 03/02/2023) (3)
Mar 2, 2023	176	NOTICE to Take Deposition of Vern Davenport Pursuant to Rule 30(b)(1) on May 23, 2023 filed by Bionpharma Inc..(Phillips, John) (Entered: 03/02/2023) (3)
Mar 2, 2023	177	NOTICE to Take Deposition of Amit M. Patel on June 29, 2023 filed by Bionpharma Inc..(Phillips, John) (Entered: 03/02/2023) (3)
Mar 2, 2023	178	NOTICE to Take Deposition of Richard A. Blackburn on May 16, 2023 filed by Bionpharma Inc..(Phillips, John) (Entered: 03/02/2023) (3)
Mar 2, 2023	179	NOTICE to Take Deposition of Gerold L. Mosher on June 20, 2023 filed by Bionpharma Inc..(Phillips, John) (Entered: 03/02/2023) (3)
Mar 2, 2023	180	NOTICE to Take Deposition of Jeff Edwards on May 30, 2023 filed by Bionpharma Inc..(Phillips, John) (Entered: 03/02/2023) (3)
Mar 2, 2023	181	NOTICE to Take Deposition of Frank Leo on June 1, 2023 filed by Bionpharma Inc..(Phillips, John) (Entered: 03/02/2023) (3)
Mar 1, 2023	172	AMENDED SCHEDULING ORDER: Fact Discovery completed by 7/7/2023. Opening Expert Reports due by 8/11/2023. Rebuttal Expert Reports due by 9/15/2023. Expert Discovery due by 12/1/2023. A telephonic Status Conference is set for 1/23/2024 at 10:00 AM before Judge Mitchell S. Goldberg. An Oral Argument is set for 1/22/2024 at 10:00 AM in Philadelphia before Judge Mitchell S. Goldberg. Proposed Pretrial Order due by 2/9/2024. A Pretrial Conference is set for 2/20/2024 at 10:00 AM in Philadelphia before Judge Mitchell S. Goldberg. A 5-day Jury Trial is set for 3/4/2024 at 09:00 AM in Courtroom To Be Determined before Judge Mitchell S. Goldberg. Signed by Judge Mitchell S. Goldberg on 3/1/2023. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG(nmg) (Entered: 03/01/2023) (2)
Feb 24, 2023	171	NOTICE OF SERVICE of Defendant Bionpharma's Objections and Responses to Plaintiff's Second Set of Interrogatories (Nos. 11-15) filed by Bionpharma Inc..(Haney, Megan) (Entered: 02/24/2023) (2)
Feb 23, 2023	170	NOTICE OF SERVICE of Defendant Bionpharma's Second Amended Invalidity Contentions Pursuant to Delaware Default Standard Rule 4(d) and Defendant Bionpharma's Supplemental Rule 26(a)(1) Initial Disclosures filed by Bionpharma Inc..(Haney, Megan) (Entered: 02/23/2023) (2)
Feb 22, 2023	169	SO ORDERED, re 167 MOTION for Pro Hac Vice Appearance of Attorney Luke T. Shannon filed by Bionpharma Inc. Signed by Judge Mitchell S. Goldberg on 02/22/2023. (smg) (Entered: 02/22/2023) (1)
Feb 21, 2023	168	STATEMENT re (261 in 1:21-cv-01286-MSG, 165 in 1:21-cv-01455-MSG) Order, -- Joint Submission Regarding Proposed Schedule -- by Azurity Pharmaceuticals, Inc.. (Attachments: # 1 Bionpharma's Exhibits B-1 to B-4)(Dellinger, Megan) (Entered: 02/21/2023) (Main Document) (16)
Feb 21, 2023	168	STATEMENT re (261 in 1:21-cv-01286-MSG, 165 in 1:21-cv-01455-MSG) Order, -- Joint Submission Regarding Proposed Schedule -- by Azurity Pharmaceuticals, Inc.. (Attachments: # 1 Bionpharma's Exhibits B-1 to B-4)(Dellinger, Megan) (Entered: 02/21/2023) (Bionpharma's Exhibits B-1 to B-4) (23)
Feb 15, 2023	166	Official Transcript of Status Hearing held on 2/7/2023 before Judge Mitchell S. Goldberg. Court Reporter/Transcriber Michael T. Keating. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 3/8/2023. Redacted Transcript Deadline set for 3/20/2023. Release of Transcript Restriction set for 5/16/2023. (apk) (Entered: 02/15/2023) (17)
Feb 15, 2023	167	MOTION for Pro Hac Vice Appearance of Attorney Luke T. Shannon - filed by Bionpharma Inc.. (Attachments: # 1 Certification of Luke T. Shannon)(Haney, Megan) (Entered: 02/15/2023) (Main Document) (1)
Feb 15, 2023	167	MOTION for Pro Hac Vice Appearance of Attorney Luke T. Shannon - filed by Bionpharma Inc.. (Attachments: # 1 Certification of Luke T. Shannon)(Haney, Megan) (Entered: 02/15/2023) (Certification of Luke T. Shannon) (2)
Feb 7, 2023	165	ORDER: By February 21, 2023, the parties shall jointly file a proposed schedule or schedules with dates for all remaining case deadlines. Competing schedules shall be set out in a table comparing the respective proposed dates and accompanied by a brief explanation of each party's position. Signed by Judge Mitchell S. Goldberg on 02/07/2023. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG(smg) (Entered: 02/07/2023) (1)
Jan 26, 2023	164	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding District of New Jersey Novitium Suit. (Attachments: # 1 Exhibit A)(Phillips, John) (Entered: 01/26/2023) (Main Document) (2)
Jan 26, 2023	164	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding District of New Jersey Novitium Suit. (Attachments: # 1 Exhibit A)(Phillips, John) (Entered: 01/26/2023) (Exhibit A) (11)
Jan 25, 2023	163	ANSWER to 46 Answer to Complaint, Counterclaim by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 01/25/2023) (30)
Jan 19, 2023	162	ORDER, a STATUS CONFERENCE in the above-captioned cases is scheduled for Tuesday, February 7, 2023 at 2:30 p.m. The conference will be held on the record via video. A link will be provided to counsel in advance of the conference. Signed by Judge Mitchell S. Goldberg on 1/19/2023. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG(twk) (Entered: 01/19/2023) (1)
Jan 13, 2023	161	ORDER, the Memorandum Opinion and Order filed in the above-captioned case on January 6, 2023 (D.I. 156 and D.I. 157 ) are VACATED. Signed by Judge Mitchell S. Goldberg on 1/13/2023. (nmg) (Entered: 01/13/2023) (1)
Jan 11, 2023	158	MEMORANDUM OPINION. Signed by Judge Mitchell S. Goldberg on 1/11/2023. (apk) (Entered: 01/11/2023) (19)
Jan 11, 2023	159	ORDER, Upon consideration of Plaintiff's Motions to Dismiss the Counterclaims or to Bifurcate and Stay Them (ECF No. 148 in 21-1286 and ECF No. 60 in 21-1455), and the responses and replies thereto, and for the reasons set out in the accompanying memorandum opinion, it is hereby ordered that the motions to dismiss are DENIED. The motions to bifurcate and stay are HELD UNDER ADVISEMENT pending the scheduling of a status conference which will be scheduled by a separate order. Signed by Judge Mitchell S. Goldberg on 1/11/2023. (apk) (Entered: 01/11/2023) (1)
Jan 11, 2023	160	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Memorandum Opinion Correction Request. (Phillips, John) (Entered: 01/11/2023) (2)
Jan 6, 2023	156	MEMORANDUM OPINION. Signed by Judge Mitchell S. Goldberg on 1/6/2023. (apk) (Entered: 01/06/2023) (10)
Jan 6, 2023	157	ORDER, Upon consideration of Defendant's Motion for Judgment on the Pleadings (ECF No. 172 in 21-1286), and the responses and replies thereto, and for the reasons set out in the accompanying memorandum opinion, it is hereby ordered that the Motion is DENIED. Signed by Judge Mitchell S. Goldberg on 1/6/2023. (apk) (Entered: 01/06/2023) (1)
Dec 14, 2022	155	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Bionpharma's Response to Plaintiff's December 13, 2022 Letter. (Phillips, John) (Entered: 12/14/2022) (3)
Dec 13, 2022	154	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding subsequent authority - re (148 in 1:21-cv-01286-MSG) MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them, (60 in 1:21-cv-01455-MSG) MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 12/13/2022) (Main Document) (1)
Dec 13, 2022	154	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding subsequent authority - re (148 in 1:21-cv-01286-MSG) MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them, (60 in 1:21-cv-01455-MSG) MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 12/13/2022) (Exhibit A) (12)
Dec 7, 2022	152	REDACTED VERSION of (244 in 1:21-cv-01286-MSG, 147 in 1:21-cv-01455-MSG) Exhibit to a Document, by Bionpharma Inc.. (Phillips, John) (Entered: 12/07/2022) (28)
Dec 7, 2022	153	ORDER, Defendant's Motion to Stay Proceedings (ECF No. 213 ) is GRANTED. Plaintiff's Motion to Stay Antitrust Discovery (ECF No. 156 ) is DENIED AS MOOT. All discovery in this case is STAYED pending disposition of Plaintiff's Motion to Dismiss and Defendant's Motion for Judgment on the Pleadings, at which time a status conference will be scheduled. Signed by Judge Mitchell S. Goldberg on 12/7/2022. (apk) (Entered: 12/07/2022) (1)
Dec 6, 2022	151	Official Transcript of Status Hearing Teleconference held on 11/30/2022 before Judge Mitchell S. Goldberg. Court Reporter/Transcriber Michael T. Keating, TK Transcribers: 609-440-2177). Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 12/27/2022. Redacted Transcript Deadline set for 1/6/2023. Release of Transcript Restriction set for 3/6/2023. (srs) (Entered: 12/06/2022) (17)
Dec 5, 2022	150	REDACTED VERSION of (143 in 1:21-cv-01455-MSG, 240 in 1:21-cv-01286-MSG) Letter by Azurity Pharmaceuticals, Inc.. (Attachments: # 1 Exhibits A-L)(Dellinger, Megan) (Entered: 12/05/2022) (Main Document) (4)
Dec 5, 2022	150	REDACTED VERSION of (143 in 1:21-cv-01455-MSG, 240 in 1:21-cv-01286-MSG) Letter by Azurity Pharmaceuticals, Inc.. (Attachments: # 1 Exhibits A-L)(Dellinger, Megan) (Entered: 12/05/2022) (Exhibits A-L) (30)
Dec 1, 2022	149	NOTICE OF SERVICE of Defendant Bionpharma's Objections and Responses to Plaintiff Azurity's Fifth Set of Requests for Production of Documents (Nos. 81-120) filed by Bionpharma Inc..(Haney, Megan) (Entered: 12/01/2022) (2)
Nov 30, 2022	145	REPLY BRIEF re 116 MOTION to Stay Proceedings filed by Bionpharma Inc.. (Phillips, John) (Entered: 11/30/2022) (18)
Nov 30, 2022	146	DECLARATION re (145 in 1:21-cv-01455-MSG) Reply Brief by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit F)(Phillips, John) (Entered: 11/30/2022) (Main Document) (3)
Nov 30, 2022	147	[SEALED] EXHIBIT re (243 in 1:21-cv-01286-MSG, 146 in 1:21-cv-01455-MSG) Declaration Exhibit E to Declaration of Roshan P. Shrestha in Support of Bionpharma's Reply Brief for its Motion to Stay by Bionpharma Inc.. (Phillips, John) (Entered: 11/30/2022) (0)
Nov 30, 2022	148	REDACTED VERSION of (238 in 1:21-cv-01286-MSG) Answering Brief in Opposition, (141 in 1:21-cv-01455-MSG) Answering Brief in Opposition by Azurity Pharmaceuticals, Inc.. (Attachments: # 1 Exhibits 1-14)(Dellinger, Megan) (Entered: 11/30/2022) (Main Document) (27)
Nov 30, 2022	148	REDACTED VERSION of (238 in 1:21-cv-01286-MSG) Answering Brief in Opposition, (141 in 1:21-cv-01455-MSG) Answering Brief in Opposition by Azurity Pharmaceuticals, Inc.. (Attachments: # 1 Exhibits 1-14)(Dellinger, Megan) (Entered: 11/30/2022) (Exhibits 1-14) (30)
Nov 30, 2022	146	DECLARATION re (145 in 1:21-cv-01455-MSG) Reply Brief by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit F)(Phillips, John) (Entered: 11/30/2022) (Exhibit A) (9)
Nov 30, 2022	146	DECLARATION re (145 in 1:21-cv-01455-MSG) Reply Brief by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit F)(Phillips, John) (Entered: 11/30/2022) (Exhibit B) (2)
Nov 30, 2022	146	DECLARATION re (145 in 1:21-cv-01455-MSG) Reply Brief by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit F)(Phillips, John) (Entered: 11/30/2022) (Exhibit C) (7)
Nov 30, 2022	146	DECLARATION re (145 in 1:21-cv-01455-MSG) Reply Brief by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit F)(Phillips, John) (Entered: 11/30/2022) (Exhibit D) (7)
Nov 30, 2022	146	DECLARATION re (145 in 1:21-cv-01455-MSG) Reply Brief by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit F)(Phillips, John) (Entered: 11/30/2022) (Exhibit F) (6)
Nov 29, 2022	144	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Response to Plaintiff Azurity's letter brief submitted to the Court yesterday (D.I. 240) - re (143 in 1:21-cv-01455-MSG, 240 in 1:21-cv-01286-MSG) Letter. (Phillips, John) (Entered: 11/29/2022) (4)
Nov 28, 2022	142	NOTICE OF SERVICE of Defendant Bionpharma's Objections and Responses to Plaintiff Azurity's Fourth Set of Requests for the Production of Documents (Nos. 71-80) filed by Bionpharma Inc..(Phillips, John) (Entered: 11/28/2022) (2)
Nov 28, 2022	143	[SEALED] Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding discovery dispute. (Attachments: # 1 Exhibits A-L)(Dellinger, Megan) (Entered: 11/28/2022) (0)
Nov 23, 2022	141	[SEALED] ANSWERING BRIEF in Opposition re 116 MOTION to Stay Proceedings filed by Azurity Pharmaceuticals, Inc..Reply Brief due date per Local Rules is 11/30/2022. (Attachments: # 1 Exhibits 1-14)(Dellinger, Megan) (Entered: 11/23/2022) (0)
Nov 22, 2022	140	NOTICE OF SERVICE of (1) Second Supplemental Initial Disclosures Pursuant to Rule 26(a)(1); and (2) Second Supplemental Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/22/2022) (3)
Nov 21, 2022	138	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding the November 30, 2022 Status Conference. (Phillips, John) (Entered: 11/21/2022) (2)
Nov 21, 2022	139	ORDER, The STATUS CONFERENCE scheduled for Wednesday, November 30, 2022 at 3:00 p.m. will be held on the record via video. A link will be provided to the parties in advance of the conference. Signed by Judge Mitchell S. Goldberg on 11/21/2022. (apk) (Entered: 11/21/2022) (1)
Nov 18, 2022	137	REDACTED VERSION of (223 in 1:21-cv-01286-MSG, 126 in 1:21-cv-01455-MSG) Letter by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan) (Entered: 11/18/2022) (30)
Nov 16, 2022	136	REDACTED VERSION of (119 in 1:21-cv-01455-MSG, 216 in 1:21-cv-01286-MSG) Exhibit to a Document by Bionpharma Inc.. (Phillips, John) (Entered: 11/16/2022) (30)
Nov 15, 2022	134	ORDER, A Status Conference will be held on Wednesday, November 30, 2022 at 3:00 p.m. at 601 Market Street, Philadelphia, in Courtroom 17-A. Additional topics to be covered include this case's status and current schedule, antitrust discovery conducted to date, including any outstanding antitrust discovery, any further antitrust discovery required and the schedule for conducting such discovery, and Plaintiff's request to stay antitrust discovery and Defendant's request to stay all discovery pending disposition of motions.( A Status Conference is set for 11/30/2022 at 03:00 PM in Philadelphia before Judge Mitchell S. Goldberg). Signed by Judge Mitchell S. Goldberg on 11/15/2022. (apk) (Entered: 11/15/2022) (2)
Nov 15, 2022	135	NOTICE requesting Clerk to remove Nicholas Halkowski as co-counsel. Reason for request: No Longer with Firm. (Dellinger, Megan) (Entered: 11/15/2022) (3)
Nov 14, 2022	132	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding response to the letter Plaintiff Azurity submitted to the Court on Friday - re (223 in 1:21-cv-01286-MSG, 126 in 1:21-cv-01455-MSG) Letter. (Phillips, John) (Entered: 11/14/2022) (2)
Nov 14, 2022	133	NOTICE of Subpoenas by Azurity Pharmaceuticals, Inc. (Dellinger, Megan) (Entered: 11/14/2022) (3)
Nov 11, 2022	124	NOTICE of Subpoenas to Novitium Pharma, LLC by Azurity Pharmaceuticals, Inc. (Dellinger, Megan) (Entered: 11/11/2022) (3)
Nov 11, 2022	125	NOTICE OF SERVICE of Second Set of Interrogatories to Bionpharma (Nos. 11-15) filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/11/2022) (3)
Nov 11, 2022	126	[SEALED] Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding discovery dispute - re (121 in 1:21-cv-01455-MSG, 218 in 1:21-cv-01286-MSG) Letter. (Attachments: # 1 Exhibits A-E)(Dellinger, Megan) (Entered: 11/11/2022) (0)
Nov 11, 2022	127	NOTICE to Take Deposition of Bill Winters on at a date mutually agreed upon by counsel filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/11/2022) (3)
Nov 11, 2022	128	NOTICE to Take Deposition of Nithya Murthy on at a date mutually agreed upon by counsel filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/11/2022) (3)
Nov 11, 2022	129	NOTICE to Take Deposition of Phanindranath Punji on at a date mutually agreed upon by counsel filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/11/2022) (3)
Nov 11, 2022	130	NOTICE to Take Deposition of Sreelatha Paniker on at a date mutually agreed upon by counsel filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/11/2022) (3)
Nov 11, 2022	131	NOTICE to Take Deposition of Usha Sankaran on at a date mutually agreed upon by counsel filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/11/2022) (3)
Nov 10, 2022	121	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Bionpharma's response to Azuritys Letter - re (120 in 1:21-cv-01455-MSG, 217 in 1:21-cv-01286-MSG) Letter. (Phillips, John) (Entered: 11/10/2022) (2)
Nov 10, 2022	122	NOTICE OF SERVICE of Defendant Bionpharma's Objections and Responses to Plaintiff Azurity's Third Set of Requests for Production of Documents (Nos. 36-70) filed by Bionpharma Inc..(Haney, Megan) (Entered: 11/10/2022) (3)
Nov 10, 2022	123	NOTICE OF SERVICE of Plaintiff Azurity Pharmaceuticals, Inc.'s Notice of Rule 30(B)(6) Deposition of Defendant Bionpharma Inc. filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/10/2022) (3)
Nov 9, 2022	116	MOTION to Stay Proceedings - filed by Bionpharma Inc.. (Attachments: # 1 Proposed Order)(Phillips, John) (Entered: 11/09/2022) (Main Document) (3)
Nov 9, 2022	117	OPENING BRIEF in Support re 116 MOTION to Stay Proceedings filed by Bionpharma Inc..Answering Brief/Response due date per Local Rules is 11/23/2022. (Phillips, John) (Entered: 11/09/2022) (24)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Main Document) (7)
Nov 9, 2022	119	[SEALED] EXHIBIT re (215 in 1:21-cv-01286-MSG, 118 in 1:21-cv-01455-MSG) Declaration,,, Exhibit J by Bionpharma Inc.. (Phillips, John) (Entered: 11/09/2022) (0)
Nov 9, 2022	120	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding discovery dispute. (Dellinger, Megan) (Entered: 11/09/2022) (2)
Nov 9, 2022	116	MOTION to Stay Proceedings - filed by Bionpharma Inc.. (Attachments: # 1 Proposed Order)(Phillips, John) (Entered: 11/09/2022) (Proposed Order) (1)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit A) (6)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit B) (19)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit C) (21)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit D) (30)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit E) (10)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit F) (12)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit G) (15)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit H) (11)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit I) (4)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit K) (30)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit L) (30)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit M) (6)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit N) (30)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit O) (9)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit P) (11)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit Q) (16)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit R) (7)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit S) (2)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit T) (3)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit U) (5)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit V) (10)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit W) (30)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit X) (3)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit Y) (14)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit Z) (30)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit AA) (6)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit BB) (12)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit CC) (4)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit DD) (2)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit EE) (18)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit FF) (18)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit GG) (18)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit HH) (18)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit II) (20)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit JJ) (4)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit KK) (12)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit LL) (2)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit MM) (4)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit NN) (4)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit OO) (3)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit PP) (30)
Nov 9, 2022	118	DECLARATION re (117 in 1:21-cv-01455-MSG) Opening Brief in Support, (214 in 1:21-cv-01286-MSG) Opening Brief in Support of Roshan P. Shrestha, Ph.D. by Bionpharma Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit K, # 11 Exhibit L, # 12 Exhibit M, # 13 Exhibit N, # 14 Exhibit O, # 15 Exhibit P, # 16 Exhibit Q, # 17 Exhibit R, # 18 Exhibit S, # 19 Exhibit T, # 20 Exhibit U, # 21 Exhibit V, # 22 Exhibit W, # 23 Exhibit X, # 24 Exhibit Y, # 25 Exhibit Z, # 26 Exhibit AA, # 27 Exhibit BB, # 28 Exhibit CC, # 29 Exhibit DD, # 30 Exhibit EE, # 31 Exhibit FF, # 32 Exhibit GG, # 33 Exhibit HH, # 34 Exhibit II, # 35 Exhibit JJ, # 36 Exhibit KK, # 37 Exhibit LL, # 38 Exhibit MM, # 39 Exhibit NN, # 40 Exhibit OO, # 41 Exhibit PP, # 42 Exhibit QQ)(Phillips, John) (Entered: 11/09/2022) (Exhibit QQ) (2)
Nov 8, 2022	114	NOTICE of Withdrawal of Its Motion to Stay Antitrust Discovery Pending Resolution of Motion to Dismiss by Azurity Pharmaceuticals, Inc. re (156 in 1:21-cv-01286-MSG, 68 in 1:21-cv-01455-MSG) MOTION to Stay Antitrust Discovery Pending Resolution of the Motion to Dismiss (Dellinger, Megan) (Entered: 11/08/2022) (3)
Nov 8, 2022	115	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding notice of withdrawal of motion - re (211 in 1:21-cv-01286-MSG, 114 in 1:21-cv-01455-MSG) Notice (Other),. (Dellinger, Megan) (Entered: 11/08/2022) (1)
Nov 1, 2022	110	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding resolution of discovery disputes. (Dellinger, Megan) (Entered: 11/01/2022) (1)
Nov 1, 2022	111	ORDER, the DISCOVERY CONFERENCE in the above-captioned cases scheduled for Thursday, November 3, 2022 at 3:00 p.m. is CANCELLED. Signed by Judge Mitchell S. Goldberg on 11/1/2022. (twk) (Entered: 11/01/2022) (1)
Nov 1, 2022	112	NOTICE to Take Deposition of Venkat Krishnan on December 6, 2022 filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/01/2022) (3)
Nov 1, 2022	113	NOTICE OF SERVICE of Fifth Set of Requests for Production to Bionpharma (Nos. 81-120) filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 11/01/2022) (3)
Oct 28, 2022	109	NOTICE OF SERVICE of Fourth Set of Requests for Production to Bionpharma (Nos. 71-80) filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 10/28/2022) (3)
Oct 26, 2022	108	ORDER granting 107 Motion to Appear Pro Hac Vice Appearance of Attorney Jody Karol. Signed by Judge Mitchell S. Goldberg on 10/26/2022. (srs) (Entered: 10/26/2022) (1)
Oct 25, 2022	107	MOTION for Pro Hac Vice Appearance of Attorney Jody Karol - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan) (Entered: 10/25/2022) (3)
Oct 11, 2022	106	NOTICE OF SERVICE of Plaintiff Azurity Pharmaceuticals, Inc.'s Third Set of Requests for Production to Bionpharma (Nos. 36-70) filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 10/11/2022) (3)
Oct 10, 2022	105	NOTICE OF SERVICE of (1) Supplemental Initial Disclosures Pursuant to Rule 26(a)(1); and (2) Supplemental Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 10/10/2022) (3)
Oct 7, 2022	104	NOTICE OF SERVICE of Supplementation of Accused Products filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan) (Entered: 10/07/2022) (3)
Oct 4, 2022	103	ORDER, A Discovery Conference is scheduled for Thursday, November 3, 2022 at 3:00 p.m. The Conference will be conducted by telephone and held on the record. Counsel are directed to dial in as follows: (1) Call: 888-684-8852; (2) Enter access code: 2187450#; (3) Press # to enter as a participant. Signed by Judge Mitchell S. Goldberg on 10/4/2022. (apk) (Entered: 10/04/2022) (1)
Sep 30, 2022	102	Letter to the Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Request for Discovery Dispute Teleconference. (Phillips, John) (Entered: 09/30/2022) (2)
Sep 22, 2022	101	Joint PROPOSED ORDER -- [Proposed] Stipulated Protective Order -- by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan) (Entered: 09/22/2022) (27)
Sep 21, 2022	100	ORDER, Azurity's request to modify paragraph 3 of Judge Stark's January 27, 2022 Scheduling Order is DENIED. The parties shall submit and docket the Protective Order entered in Civil Action Nos. 18-1962-LPS (D.I. 34) and 19-1067-LPS (D.I. 21) in the instant action. (See Order for further details) Signed by Judge Mitchell S. Goldberg on 09/21/2022. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG(smg) (Entered: 09/21/2022) (4)
Sep 16, 2022	99	Official Transcript of Discovery Hearing held on 09/14/2022 before Judge Goldberg. Court Reporter/Transcriber TK Transcribers, contact: 609-440-2177. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 10/7/2022. Redacted Transcript Deadline set for 10/17/2022. Release of Transcript Restriction set for 12/15/2022. Associated Cases: 1:18-cv-01962-MSG et al.(smg) (Entered: 09/16/2022) (17)
Sep 14, 2022	98	ORDER, the time for the DISCOVERY CONFERENCE in the above-captioned matter scheduled for Wednesday, September 14, 2022 is changed from 4:00 p.m. to 3:00 p.m. Counsel are directed to dial in as follows: (1) Call: 888-684-8852; (2) Enter access code: 2187450#; (3) Press # to enter as a participant. Signed by Judge Mitchell S. Goldberg on 9/14/2022. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG(srs) (Entered: 09/14/2022) (1)
Sep 13, 2022	97	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding Protective Order dispute - re (192 in 1:21-cv-01286-MSG, 95 in 1:21-cv-01455-MSG) Letter,. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) (Entered: 09/13/2022) (Main Document) (5)
Sep 13, 2022	97	Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding Protective Order dispute - re (192 in 1:21-cv-01286-MSG, 95 in 1:21-cv-01455-MSG) Letter,. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) (Entered: 09/13/2022) (Exhibits 1-4) (30)
Sep 12, 2022	95	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Letter Brief Regarding the Parties' Protective Order Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Phillips, John) (Entered: 09/12/2022) (Main Document) (5)
Sep 12, 2022	96	NOTICE OF SERVICE of Defendant Bionpharma's First Amended Invalidity Contentions Pursuant to Delaware Default Standard Rule 4(d) filed by Bionpharma Inc..(Haney, Megan) (Entered: 09/12/2022) (3)
Sep 12, 2022	95	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Letter Brief Regarding the Parties' Protective Order Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Phillips, John) (Entered: 09/12/2022) (Exhibit A) (29)
Sep 12, 2022	95	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Letter Brief Regarding the Parties' Protective Order Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Phillips, John) (Entered: 09/12/2022) (Exhibit B) (6)
Sep 12, 2022	95	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Letter Brief Regarding the Parties' Protective Order Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Phillips, John) (Entered: 09/12/2022) (Exhibit C) (12)
Sep 12, 2022	95	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Letter Brief Regarding the Parties' Protective Order Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Phillips, John) (Entered: 09/12/2022) (Exhibit D) (3)
Sep 12, 2022	95	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Letter Brief Regarding the Parties' Protective Order Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Phillips, John) (Entered: 09/12/2022) (Exhibit E) (30)
Sep 12, 2022	95	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Letter Brief Regarding the Parties' Protective Order Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Phillips, John) (Entered: 09/12/2022) (Exhibit F) (30)
Sep 12, 2022	95	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Letter Brief Regarding the Parties' Protective Order Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Phillips, John) (Entered: 09/12/2022) (Exhibit G) (30)
Sep 12, 2022	95	Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Defendant Bionpharma's Letter Brief Regarding the Parties' Protective Order Dispute. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H)(Phillips, John) (Entered: 09/12/2022) (Exhibit H) (6)
Sep 8, 2022	94	ORDER, the DISCOVERY CONFERENCE in the above-captioned matter scheduled for Wednesday, September 14, 2022 is changed from 2:00 p.m. to 4:00 PM. Counsel are directed to dial in as follows: (1) Call: 888-684-8852; (2) Enter access code: 2187450#; (3) Press # to enter as a participant. Signed by Judge Mitchell S. Goldberg on 09/08/2022. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG(smg) (Entered: 09/08/2022) (1)
Sep 1, 2022	93	ORDER, A Discovery Conference in the above-captioned matter is scheduled for Wednesday, September 14, 2022 at 2:00 p.m. The Conference will be conducted by telephone and held on the record. Counsel are directed to dial in as follows: (1) Call: 888-684-8852 (2) Enter access code: 2187450#; (3) Press # to enter as a participant.( A Discovery Conference is set for 9/14/2022 at 02:00 PM Telephonically before Judge Mitchell S. Goldberg.). Signed by Judge Mitchell S. Goldberg on 9/1/2022. (apk) (Entered: 09/01/2022) (1)
Aug 8, 2022	92	Interim STATUS REPORT by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan) (Entered: 08/08/2022) (3)
Jul 29, 2022	90	Letter (2) Docket Text: Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding response to Bionpharma's letter - re (89 in 1:21-cv-01455-MSG, 182 in 1:21-cv-01286-MSG) Letter. (Dellinger, Megan)
Jul 29, 2022	91	Letter (2) Docket Text: Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Response to Plaintiff Azurity's July 29, 2022 letter. (Phillips, John)
Jul 28, 2022	89	Letter (3) Docket Text: Letter to The Honorable Mitchell S. Goldberg from John C. Phillips, Jr. regarding Supplemental Authority. (Phillips, John)
Jul 27, 2022	N/A	Case No Longer Referred to Mediation (0) Docket Text: CASE NO LONGER REFERRED to Magistrate Judge Burke for the purpose of exploring ADR. Please see the Court's Standing Order No. 2022-2 dated March 14, 2022. (dlb)
Jul 26, 2022	88	Main Document (1) Docket Text: Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding subsequent authority - re (148 in 1:21-cv-01286-MSG) MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them, (60 in 1:21-cv-01455-MSG) MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them. (Attachments: # (1) Exhibit A)(Dellinger, Megan)
Jul 26, 2022	88	Exhibit A (14)
Jul 22, 2022	87	Notice of Service (3) Docket Text: NOTICE OF SERVICE of Objections and Responses to Defendant Bionpharma's Second Set of Interrogatories (Nos. 5-9) filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
Jul 18, 2022	86	Stipulation and Order (1) Docket Text: STIPULATION AND ORDER, re [85] STIPULATION TO EXTEND TIME for the parties to submit the joint interim status report to August 8, 2022. Signed by Judge Mitchell S. Goldberg on 7/18/2022. (twk)
Jul 8, 2022	85	Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit the joint interim status report to August 8, 2022 - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Jul 7, 2022	84	Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendant Bionpharma's Objections and Responses to Plaintiff Azurity's Second Set of Requests for Production of Documents (Nos. 33-35) filed by Bionpharma Inc..(Haney, Megan)
Jun 27, 2022	83	Notice of Service (3) Docket Text: NOTICE OF SERVICE of Objections and Responses to Defendant Bionpharma's Second Set of Requests for Production of Documents and Things (Nos. 69-99) filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
Jun 22, 2022	82	Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Bionpharma's Second Set of Interrogatories filed by Bionpharma Inc..(Haney, Megan)
Jun 21, 2022	81	Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendant Bionpharma's Invalidity Contentions Pursuant to Delaware Default Standard Rule 4(d) filed by Bionpharma Inc..(Haney, Megan)
Jun 9, 2022	80	Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendant Bionpharma's Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-10) and Defendant Bionpharma's Objections and Responses to Plaintiff Azurity's First Set of Requests for Production of Documents (Nos. 1-32) filed by Bionpharma Inc..(Haney, Megan)
Jun 7, 2022	79	Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiff Azurity Pharmaceuticals, Inc.'s Second Set of Requests for Production to Bionpharma (Nos. 33-35) - filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
May 17, 2022	78	Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendant Bionpharma's Second Set of Requests for Production of Documents and Things (Nos. 69-99) filed by Bionpharma Inc..(Haney, Megan)
May 12, 2022	76	Request for Oral Argument (3) Docket Text: REQUEST for Oral Argument by Azurity Pharmaceuticals, Inc. re (148 in 1:21-cv-01286-MSG) MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them, (60 in 1:21-cv-01455-MSG) MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them. (Dellinger, Megan)
May 12, 2022	77	Reply Brief (16) Docket Text: REPLY BRIEF re [68] MOTION to Stay Antitrust Discovery Pending Resolution of the Motion to Dismiss filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
May 10, 2022	75	Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) First Set of Requests for Production to Bionpharma (Nos. 1-32); and (2) First Set of Interrogatories to Bionpharma (Nos. 1-10) filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
May 5, 2022	73	Answering Brief in Opposition (28) Docket Text: ANSWERING BRIEF in Opposition re [68] MOTION to Stay Antitrust Discovery Pending Resolution of the Motion to Dismiss filed by Bionpharma Inc..Reply Brief due date per Local Rules is 5/12/2022. (Phillips, John)
May 5, 2022	74	Reply Brief (18) Docket Text: REPLY BRIEF re [60] MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
May 2, 2022	72	Transcript (57) Docket Text: Official Transcript of Status Hearing held on 4/25/2022 before Judge Mitchell S. Goldberg. Court Reporter/Transcriber Michael T. Keating, Phone: (609) 440-2177. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 5/23/2022. Redacted Transcript Deadline set for 6/2/2022. Release of Transcript Restriction set for 8/1/2022. Associated Cases: 1:18-cv-01962-MSG et al.(nmg)
Apr 26, 2022	71	Stipulation and Order (1) Docket Text: STIPULATION AND ORDER re (158 in 1:21-cv-01286-MSG, 70 in 1:21-cv-01455-MSG) STIPULATION TO EXTEND TIME for the parties to submit the joint interim status report to July 8, 2022. Signed by Judge Mitchell S. Goldberg on 4/26/2022. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG. (nmg)
Apr 25, 2022	N/A	Status Conference (0) Docket Text: Minute Entry for proceedings held before Judge Mitchell S. Goldberg - Zoom Status Conference held on 4/25/2022. (Court Reporter Jimmy Cruz.) Associated Cases: 1:18-cv-01962-MSG et al. (nmg)
Apr 22, 2022	70	Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit the joint interim status report to July 8, 2022 - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Apr 21, 2022	67	Main Document (28) Docket Text: ANSWERING BRIEF in Opposition re [60] MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them filed by Bionpharma Inc..Reply Brief due date per Local Rules is 4/28/2022. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C)(Phillips, John)
Apr 21, 2022	67	Exhibit A (52)
Apr 21, 2022	67	Exhibit B (7)
Apr 21, 2022	67	Exhibit C (8)
Apr 21, 2022	68	Motion to Stay (4) Docket Text: MOTION to Stay Antitrust Discovery Pending Resolution of the Motion to Dismiss - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Apr 21, 2022	69	Main Document (18) Docket Text: OPENING BRIEF in Support re [68] MOTION to Stay Antitrust Discovery Pending Resolution of the Motion to Dismiss filed by Azurity Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 5/5/2022. (Attachments: # (1) Exhibits A-E)(Dellinger, Megan)
Apr 21, 2022	69	Exhibits A-E (74)
Apr 20, 2022	66	Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Objections and Responses to Defendant Bionpharma's First Set of Requests for Production of Documents and Things; and (2) Objections and Responses to Defendant Bionpharma's First Set of Interrogatories filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
Apr 18, 2022	65	Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiff Azurity Pharmaceuticals, Inc.'s Initial Infringement Claim Charts filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
Apr 13, 2022	64	Status Report (9) Docket Text: Joint STATUS REPORT by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Mar 30, 2022	63	Order (2) Docket Text: ORDER, A status conference will be held on the record, by video conference, on Monday, April 25, 2022, at 3:00 p.m. Chambers will contact the parties with details for joining the video conference. Counsel for all parties shall meet and confer and, within fourteen (14) days of the date of this Order, file a joint letter summarizing the status of each of the above cases. Signed by Judge Mitchell S. Goldberg on 3/30/2022. Associated Cases: 1:18-cv-01962-MSG et al. (nmg)
Mar 25, 2022	62	Order on Motion to Appear Pro Hac Vice (3) Docket Text: ORDER granting (146) MOTION for Pro Hac Vice Appearance of Attorney Alexander Poonai in case 1:21-cv-01286-MSG; granting (58) MOTION for Pro Hac Vice Appearance of Attorney Alexander Poonai in case 1:21-cv-01455-MSG. Signed by Judge Mitchell S. Goldberg on 3/25/2022. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG(nmg)
Mar 24, 2022	60	Motion to Dismiss for Failure to State a Claim (4) Docket Text: MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Mar 24, 2022	61	Main Document (29) Docket Text: OPENING BRIEF in Support re [60] MOTION to Dismiss for Failure to State a Claim (Counts III and IV of Bionpharma's Counterclaims) or, in the Alternative, to Bifurcate and Stay Them filed by Azurity Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 4/7/2022. (Attachments: # (1) Exhibits 1-4)(Dellinger, Megan)
Mar 24, 2022	61	Exhibits 1-4 (69)
Mar 23, 2022	58	Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Alexander Poonai - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Mar 23, 2022	59	Order (1) Docket Text: ORDER, the parties having advised that no claim construction hearing is needed as there are no claim terms in dispute, it is hereby ORDERED that: The claim construction hearing scheduled for June 21, 2022 is adjourned. The associated deadlines for tutorial, issue identification, and briefing (ECF No. [126] at 10-13) are likewise adjourned. Signed by Judge Mitchell S. Goldberg on 3/23/2022. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG(nmg)
Mar 22, 2022	57	Stipulation and Order (2) Docket Text: STIPULATION AND ORDER. Azurity's Motion to Dismiss is due on 3/24/2022. Bionpharma's Answering Brief is due on 4/21/22 and Azurity's Reply Brief is due on 5/5/2022. Signed by Judge Mitchell S. Goldberg on 3/22/22. Associated Cases: 1:21-cv-01286-MSG, 1:21-cv-01455-MSG(mal)
Mar 21, 2022	56	Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Bionpharma's First Set of Interrogatories and (2) Bionpharma's First Set of Requests for Production of Documents and Things filed by Bionpharma Inc..(Haney, Megan)
Mar 16, 2022	55	Letter (1) Docket Text: Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding request that the Court cancel the Markman hearing scheduled for June 21, 2022 and remove associated deadlines from calendar. (Dellinger, Megan)
Mar 8, 2022	53	Stipulation (2) Docket Text: STIPULATION and [Proposed] Order Regarding Motion to Dismiss Briefing re (46 in 1:21-cv-01455-MSG, 46 in 1:21-cv-01455-MSG) Answer to Complaint, Counterclaim, (135 in 1:21-cv-01286-MSG, 135 in 1:21-cv-01286-MSG) Answer to Amended Complaint, Counterclaim by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Mar 8, 2022	54	Claim Construction Chart (3) Docket Text: CLAIM Construction Chart by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Mar 2, 2022	N/A	Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Mitchell S. Goldberg of the United States District Court for the Eastern District of Pennsylvania. Please include the initials of the Judge (MSG) after the case number on all documents filed. Associated Cases: 1:18-cv-01962-MSG, 1:19-cv-01067-MSG, 1:19-cv-02100-MSG, 1:20-cv-01256-MSG, 1:21-cv-00196-MSG, 1:21-cv-01286-MSG, 1:21-cv-01455-MSG, and 1:21-cv-01707-MSG. (rjb)
Feb 28, 2022	51	Notice of Service (2) Docket Text: NOTICE OF SERVICE of Bionpharma's Initial Proposed Claim Terms for Construction and Proposed Constructions filed by Bionpharma Inc..(Haney, Megan)
Feb 28, 2022	52	Notice of Service (3) Docket Text: NOTICE OF SERVICE of Disclosure of Proposed Claim Terms and Constructions for U.S. Patent Nos. 11,040,023 and 11,141,405 filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
Feb 25, 2022	50	Status Report (8) Docket Text: Joint STATUS REPORT by Azurity Pharmaceuticals, Inc., Silvergate Pharmaceuticals, Inc.. (Dellinger, Megan)
Feb 24, 2022	49	Redacted Document (30) Docket Text: REDACTED VERSION of [46] Answer to Complaint, Counterclaim by Bionpharma Inc.. (Phillips, John)
Feb 23, 2022	N/A	Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that in anticipation of reassignment of these cases (C.A. Nos. 18-1962, 19-1067, 19-2100, 21-196, 21-1286, 21-1455, 21-1707) to another judge, the parties shall meet and confer and, no later than February 25, submit a joint status report (one that collectively addresses all of these related cases), advising the Court of the following (in addition to anything else the parties wish to report): (i) whether trial has occurred and/or is scheduled to occur and if so, when; (ii) whether a preliminary injunction motion has been litigated and whether any preliminary injunction motion is anticipated; (iii) the date of expiration of any regulatory stay, if applicable; and (iv) the status of any pending motions, or any motions the parties anticipate filing, and the urgency (if any) of such motions. ORDERED by Judge Leonard P. Stark on 2/23/22. Associated Cases: 1:18-cv-01962-LPS et al. (ntl)
Feb 17, 2022	N/A	Document Unsealed (0) Docket Text: Document Unsealed -- D.I. 121 in 1:21-cv-01286-LPS; D.I. 32 in 1:21-cv-01455-LPS. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS (ntl)
Feb 17, 2022	47	Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Bionpharma Inc.. (Phillips, John)
Feb 16, 2022	N/A	SO ORDERED (0) Docket Text: SO ORDERED, re (134 in 1:21-cv-01286-LPS, 45 in 1:21-cv-01455-LPS) MOTION for Pro Hac Vice Appearance of Attorney Aaron M. Johnson & Christopher J. Kelly filed by Bionpharma Inc. Signed by Judge Leonard P. Stark on 2/16/22. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS (ntl)
Feb 16, 2022	N/A	Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Aaron M. Johnson for Bionpharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk)
Feb 16, 2022	N/A	Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher J. Kelly for Bionpharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk)
Feb 15, 2022	45	Main Document (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Aaron M. Johnson & Christopher J. Kelly - filed by Bionpharma Inc.. (Attachments: # (1) Certification of Aaron M. Johnson, # (2) Certification of Christopher J. Kelly)(Haney, Megan)
Feb 15, 2022	45	Certification of Aaron M. Johnson (1)
Feb 15, 2022	45	Certification of Christopher J. Kelly (1)
Feb 11, 2022	44	Notice of Service (2) Docket Text: NOTICE OF SERVICE of Bionpharma's Paragraph 4(b) Disclosures filed by Bionpharma Inc..(Haney, Megan)
Feb 10, 2022	42	Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Initial Disclosures Pursuant to Rule 26(a)(1); (2) Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; and (3) Identification of Accused Products and Asserted Patents Pursuant to Paragraph 4(a) of the Delaware Default Standard for Discovery filed by Azurity Pharmaceuticals, Inc..(Dellinger, Megan)
Feb 10, 2022	43	Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Bionpharma's Rule 26(a)(1) Initial Disclosures and Defendant Bionpharma's Initial Disclosures Pursuant to D. Del.'s Default Standard for Discovery filed by Bionpharma Inc..(Haney, Megan)
Feb 8, 2022	N/A	SO ORDERED (0) Docket Text: SO ORDERED, re (130 in 1:21-cv-01286-LPS, 41 in 1:21-cv-01455-LPS) STIPULATION TO EXTEND TIME for Defendant to answer, move or otherwise respond to (1) the First Amended Complaint (D.I. 89) in C.A. No. 21-1286-LPS and (2) the Complaint (D.I. 1) in C.A. No. 21-1455-LPS to February 17, 2022 filed by Bionpharma Inc. Signed by Judge Leonard P. Stark on 2/8/22. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS (ntl)
Feb 7, 2022	41	Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Defendant to answer, move or otherwise respond to (1) the First Amended Complaint (D.I. 89) in C.A. No. 21-1286-LPS and (2) the Complaint (D.I. 1) in C.A. No. 21-1455-LPS to February 17, 2022 - filed by Bionpharma Inc.. (Haney, Megan)
Feb 2, 2022	39	Redacted Document (30) Docket Text: REDACTED VERSION of (121 in 1:21-cv-01286-LPS, 32 in 1:21-cv-01455-LPS) Letter, by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Feb 2, 2022	40	Redacted Document (2) Docket Text: REDACTED VERSION of (34 in 1:21-cv-01455-LPS) Letter by Bionpharma Inc.. (Phillips, John)
Jan 27, 2022	N/A	SO ORDERED (0) Docket Text: SO ORDERED, re (122 in 1:21-cv-01286-LPS, 33 in 1:21-cv-01455-LPS) MOTION for Pro Hac Vice Appearance of Attorney Jeffrey C. Bank filed by Azurity Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 1/27/22. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS (ntl)
Jan 27, 2022	N/A	Case Referred to Mediation (0) Docket Text: CASE REFERRED to Magistrate Judge Christopher J. Burke for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at https://www.ded.uscourts.gov/sites/ded/files/forms/StandingOrderforADR-Mediation.pdf Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS(Taylor, Daniel)
Jan 27, 2022	33	Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jeffrey C. Bank - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Jan 27, 2022	N/A	Order (0) Docket Text: ORAL ORDER: Having reviewed the briefing submitted by the parties (see C.A. No. 21-1286 D.I. 98, 106, 111; C.A. No. 21-1455 D.I. 13, 17, 22), as well as the parties' letters regarding subsequent developments in the Florida CoreRx case, IT IS HEREBY ORDERED that Bionpharma's motion to dismiss (C.A. No. 21-1286 D.I. 97; C.A. No. 21-1455 D.I. 12) pursuant to Fed. R. Civ. P. 12(b)(6) is DENIED. The Court agrees with Azurity that the "two-dismissal" rule of Fed. R. Civ. P. 41(a)(1)(B) is inapplicable because both of Azurity's actions against CoreRx were dismissed pursuant to a mutual agreement between those parties, and not the unilateral action of Azurity, as is well established by the record. (See, e.g., C.A. No. 21-1286 D.I. 106 at 3; D.I. 107 para. 6-7; D.I. 120-1 para. 16; D.I. 121 Exs. A & B at 25-26; see also Azurity Pharms., Inc. v. CoreRx, Inc., C.A. No. 8:21-2515 (M.D. Fla.) D.I. 18 & Ex. A) The purpose of Rule 41(a)(1)(B)'s "two-dismissal" rule is to "prevent Plaintiffs from abusing their ability to dismiss cases and re-file cases at will, thereby harassing other parties," CAC Maritime, Ltd. v. Redbrick Ventures, Ltd., 2021 WL 3048405, at 1 (D. Del. July 20, 2021), a purpose which is not implicated by the circumstances presented here. While the two-dismissal rule is mandatory where it applies, it must also be strictly construed, and here Bionpharma has failed to show it applies to the circumstances presented, which involve joint action by Azurity and CoreRx (the Florida defendant). See id. (stating that where application of two-dismissal rule does not serve its purposes, and would "close the courthouse doors to an otherwise proper litigant," rule should not be applied broadly); see also generally St. Clair Intell. Prop. Consultants, Inc. v. Samsung Elecs. Co., 291 F.R.D. 75, 79 (D. Del. 2013). The (non-binding) cases upon which Bionpharma relies (see D.I. 111 at 2) do not compel a different conclusion but merely support the inapposite proposition that "[w]hen a plaintiff unilaterally dismisses prior lawsuits, the two-dismissal rule neither requires an inquiry into the circumstances of the two dismissals nor considers the plaintiff's reasons for seeking a voluntary dismissal." Ferretti v. Beach Club Maui, Inc., 2018 WL 3078742, at 5 (D. Haw. June 21, 2018) (internal quotation marks omitted). Bionpharma has not shown, at this point, that Azurity abused the judicial system (but this statement is without prejudice to any efforts Bionpharma may intend to take on this issue as the instant cases proceed). Additionally, because the Court agrees with Azurity that Bionpharma is not in privity with CoreRx for purposes of the two-dismissal rule, Bionpharma would not prevail on its motion even if the two-dismissal rule applied here. Although Bionpharma had a contract with CoreRx to develop the accused ANDA product, and has a contract with CoreRx to manufacture and supply the accused ANDA product to Bionpharma, a manufacturer or seller of a product who is sued for patent infringement is generally not considered to be in privity with a party who does no more than purchase and use the product. See S. Snow Mfg. Co. v. SnoWizard Holdings, Inc., 567 F. App'x 945, 960 (Fed. Cir. 2014). Bionpharma and CoreRx are wholly separate companies lacking any corporate relationship (unlike Azurity and CoreRx, which share a corporate parent), and they are represented by separate counsel; neither entity is alleged to be able to control the another with respect to litigation. The Court has considered Bionpharma's other arguments, and the additional cases it has cited, and finds none of them (alone or in combination) meets Bionpharma's burden to show that Bionpharma is the same, or substantially the same, or in privity with CoreRx, such that an adjudication on the merits with respect to CoreRx would extend to Bionpharma. IT IS FURTHER ORDERED that the hearing scheduled for tomorrow, January 28, is CANCELLED. The Court will enter a separate order setting the schedule for these cases. ORDERED by Judge Leonard P. Stark on 1/27/22. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS (ntl)
Jan 27, 2022	N/A	Order (0) Docket Text: ORAL ORDER: Having reviewed the parties' submissions relating to the proposed schedule for this case (see C.A. No. 21-1286 D.I. 116-19; C.A. No. 21-1455 D.I. 27-30), IT IS HEREBY ORDERED that the Court will, by separate order, enter a schedule to govern further proceedings, consistent with the following resolution of the parties' disputes: (1) trial will be set for February 2024, consistent with Bionpharma's request, as this date (a) provides the necessary and appropriate amount of time to complete needed new discovery (which may include patent defenses as well as antitrust counterclaims, which may or may not be stayed and would, at minimum, likely be the subject of motion practice), (b) is a more reasonable request than Azurity's proposed trial date of January 2023, which does not appear to leave sufficient time to complete discovery and all necessary pre-trial tasks, and (c) reflects the challenges of the Court's schedule and other commitments; (2) Bionpharma's proposed provision to be permitted to redact or withhold from production its correspondence with the FDA that solely relates to approval status of the ANDA is REJECTED as such correspondence is relevant (at least to damages) and the circumstances are much different now than when the Court approved such a provision in earlier cases between the parties - providing Azurity access to such correspondence may eliminate the need for further motion practice seeking extraordinary injunctive relief and/or may eliminate the need that such motion practice be expedited; and (3) Bionpharma's request for 70 hours of deposition, as provided for in the Federal Rules of Civil Procedure, is GRANTED, as it appears reasonable and proportional to the needs of the case, notwithstanding that much discovery has already been taken on many issues to be litigated in this action (but not on others, such as damages and allegations of anticompetitive conduct). ORDERED by Judge Leonard P. Stark on 1/27/22. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS (ntl)
Jan 27, 2022	37	Scheduling Order (18) Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Fact Discovery completed by 12/12/2022. Status Report due by 4/22/2022. Dispositive Motions due by 8/21/2023. AN Oral Argument is set for 10/10/2023 at 10:00 AM before Judge Leonard P. Stark. Joint Claim Construction Brief due by 6/1/2022. A Markman Hearing is set for 6/21/2022 at 10:00 AM before Judge Leonard P. Stark. Proposed Pretrial Order due by 12/4/2023. A Final Pretrial Conference is set for 12/19/2023 at 10:00 AM before Judge Leonard P. Stark. A 10-day Jury Trial is set for 2/1/2024 at 09:00 AM before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 1/27/22. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS (ntl)
Jan 27, 2022	N/A	Oral Order (0) Docket Text: ORAL ORDER: If during the history of this case, Plaintiff(s) and Defendant(s) jointly wish to schedule a form of alternative dispute resolution ("ADR"), such as mediation, with Judge Burke, they should contact chambers by e-mail at Deborah_Benyo@ded.uscourts.gov or by phone. Additionally, if either side wishes to speak ex parte with Judge Burke regarding ADR matters, they may contact chambers via e-mail or by phone to arrange a time for a call. Ordered by Judge Christopher J. Burke on 1/27/2022. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS(dlb)
Jan 26, 2022	32	Main Document (1) Docket Text: Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding recent developments relevant to Bionpharma's pending motion to dismiss - re (97 in 1:21-cv-01286-LPS) MOTION to Dismiss for Failure to State a Claim . (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Dellinger, Megan) Modified on 2/17/2022 (ntl).
Jan 26, 2022	32	Exhibit A (11)
Jan 26, 2022	32	Exhibit B (31)
Jan 25, 2022	N/A	CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Corrected Exhibit C added to D.I. 17 & 20 per request of counsel. (ntl)
Jan 24, 2022	31	Main Document (3) Docket Text: NOTICE of Subsequent Authority by Azurity Pharmaceuticals, Inc. re (97 in 1:21-cv-01286-LPS) MOTION to Dismiss for Failure to State a Claim (Attachments: # (1) Exhibit 1)(Dellinger, Megan)
Jan 24, 2022	31	Exhibit 1 (11)
Jan 20, 2022	29	Letter (3) Docket Text: Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding scheduling order disputes - re (116 in 1:21-cv-01286-LPS) Letter,. (Dellinger, Megan)
Jan 20, 2022	30	Letter (4) Docket Text: Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Bionpharma's Reply Letter Brief on Scheduling. (Phillips, John)
Jan 19, 2022	27	Letter (5) Docket Text: Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Regarding Scheduling Order Disputes - re (113 in 1:21-cv-01286-LPS, 113 in 1:21-cv-01286-LPS, 24 in 1:21-cv-01455-LPS, 24 in 1:21-cv-01455-LPS) Order,,,,,,,,, Set Hearings,,,,,,,,. (Phillips, John)
Jan 19, 2022	28	Letter (4) Docket Text: Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding scheduling order disputes - re (113 in 1:21-cv-01286-LPS, 113 in 1:21-cv-01286-LPS) Order,,,,,,,,, Set Hearings,,,,,,,,. (Dellinger, Megan)
Jan 18, 2022	26	Main Document (20) Docket Text: PROPOSED ORDER Proposed Scheduling Order by Azurity Pharmaceuticals, Inc.. (Attachments: # (1) Letter to the Honorable Judge Stark)(Dellinger, Megan)
Jan 18, 2022	26	Letter to the Honorable Judge Stark (1)
Jan 17, 2022	25	Main Document (2) Docket Text: Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Development in Florida CoreRx Suit - re (103 in 1:21-cv-01286-LPS, 15 in 1:21-cv-01455-LPS) Letter. (Attachments: # (1) Exhibit A)(Phillips, John)
Jan 17, 2022	25	Exhibit A (5)
Jan 4, 2022	N/A	Order (0) Docket Text: ORAL ORDER: Having reviewed the parties' many recent filings in C.A. No. 21-1286 (see, e.g., D.I. 97-107, 111-12), and mindful of the related case, C.A. No. 21-1455, and the filings therein, IT IS HEREBY ORDERED that: (1) Bionpharma's motion for extension of time (D.I. 99) is DENIED; (2) the parties shall meet and confer and submit a scheduling order, to govern proceedings in both above-referenced actions, no later than January 18, 2022; (3) in the event the parties have any disputes with respect to the scheduling order and/or with respect to consolidation and/or coordination of the two above-referenced actions, they shall file letter briefs according to the following schedule: (a) letter briefs not to exceed three pages per side due January 19, and (b) letter briefs not to exceed two pages per side due January 20; and (4) the Court will hear argument by teleconference on any scheduling disputes (if necessary) and on the pending motions to dismiss (C.A. No. 21-1286 D.I. 97; C.A. No. 21-1455 D.I. 12) on January 28 beginning at 10:00 a.m. - each side will have a total of up to 30 minutes for its argument. The Court finds this is a reasonable and appropriate manner of proceeding with these cases, considering all the circumstances, including the lengthy history of the parties' litigations against one another and the Court's familiarity with the parties and some of the pertinent evidence. The Court believes (for reasons including Defendant's allegations of anticompetitive conduct by Plaintiff, Defendant's suggestions of misuse of the judicial process by Plaintiff and/or Plaintiff's counsel, and the "extensive discovery" Defendant contends it will seek (C.A. No. 21-1286 D.I. 101 at 2)) this is an appropriate set of cases in which to impose a schedule, and begin discovery, notwithstanding the pendency of the motions to dismiss and the fact that Defendant has not yet had to file an answer. Counsel and any interested member of the public may access the teleconference by dialing 877-336-1829 and using the access code 1408971. ORDERED by Judge Leonard P. Stark on 1/4/22. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS (ntl)
Jan 3, 2022	23	Request for Oral Argument (1) Docket Text: REQUEST for Oral Argument by Bionpharma Inc. re (12 in 1:21-cv-01455-LPS) MOTION to Dismiss for Failure to State a Claim , (97 in 1:21-cv-01286-LPS) MOTION to Dismiss for Failure to State a Claim . (Phillips, John)
Dec 30, 2021	22	Reply Brief (18) Docket Text: REPLY BRIEF re [12] MOTION to Dismiss for Failure to State a Claim filed by Bionpharma Inc.. (Phillips, John)
Dec 28, 2021	N/A	SO ORDERED (0) Docket Text: SO ORDERED, re (108 in 1:21-cv-01286-LPS, 19 in 1:21-cv-01455-LPS) STIPULATION TO EXTEND TIME to file Reply Brief in Support of Motion to Dismiss to December 30, 2021 filed by Bionpharma Inc. Signed by Judge Leonard P. Stark on 12/28/21. Associated Cases: 1:21-cv-01286-LPS, 1:21-cv-01455-LPS (ntl)
Dec 22, 2021	20	Main Document (19) Docket Text: REDACTED VERSION of (17 in 1:21-cv-01455-LPS) Answering Brief in Opposition, (106 in 1:21-cv-01286-LPS) Answering Brief in Opposition, by Azurity Pharmaceuticals, Inc.. (Attachments: # (1) Exhibits A-E)(Dellinger, Megan) (Attachment 1 replaced on 1/25/2022) (ntl).
Dec 22, 2021	20	Exhibits A-E (193)
Dec 22, 2021	21	Redacted Document (4) Docket Text: REDACTED VERSION of (107 in 1:21-cv-01286-LPS, 18 in 1:21-cv-01455-LPS) Declaration by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Dec 21, 2021	19	Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to file Reply Brief in Support of Motion to Dismiss to December 30, 2021 - filed by Bionpharma Inc.. (Haney, Megan)
Dec 14, 2021	16	Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Florida CoreRX suit - re (103 in 1:21-cv-01286-LPS) Letter. (Dellinger, Megan)
Dec 13, 2021	15	Main Document (3) Docket Text: Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding developments in Florida CoreRx suit. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Phillips, John)
Dec 13, 2021	15	Exhibit A (5)
Dec 13, 2021	15	Exhibit B (70)
Dec 6, 2021	12	Main Document (2) Docket Text: MOTION to Dismiss for Failure to State a Claim - filed by Bionpharma Inc.. (Attachments: # (1) Text of Proposed Order)(Phillips, John)
Dec 6, 2021	12	Text of Proposed Order (1)
Dec 6, 2021	13	Main Document (20) Docket Text: OPENING BRIEF in Support re [12] MOTION to Dismiss for Failure to State a Claim filed by Bionpharma Inc..Answering Brief/Response due date per Local Rules is 12/20/2021. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Phillips, John)
Dec 6, 2021	13	Exhibit A (14)
Dec 6, 2021	13	Exhibit B (3)
Dec 6, 2021	14	Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Bionpharma Inc.. (Phillips, John)
Nov 22, 2021	N/A	SO ORDERED (0) Docket Text: SO ORDERED, re [11] STIPULATION TO EXTEND TIME for Bionpharma Inc. to answer, move or otherwise respond to the Complaint to December 6, 2021 filed by Bionpharma Inc. Signed by Judge Leonard P. Stark on 11/22/21. (ntl)
Nov 19, 2021	11	Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for Bionpharma Inc. to answer, move or otherwise respond to the Complaint to December 6, 2021 - filed by Bionpharma Inc.. (Haney, Megan)
Nov 2, 2021	N/A	Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Andrew M. Alul and Roshan P. Shrestha for Bionpharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs)
Nov 1, 2021	N/A	SO ORDERED (0) Docket Text: SO ORDERED, re [10] STIPULATION TO EXTEND TIME for Bionpharma Inc. to answer, move or otherwise respond to the Complaint to 21 days after the Court rules on Bionpharma's Motion to Dismiss in C.A. No. 21-1286-LPS filed by Bionpharma Inc. Signed by Judge Leonard P. Stark on 10/29/21. (ntl)
Nov 1, 2021	N/A	SO ORDERED (0) Docket Text: SO ORDERED, re [9] MOTION for Pro Hac Vice Appearance of Attorney Andrew M. Alul & Roshan P. Shrestha filed by Bionpharma Inc. Signed by Judge Leonard P. Stark on 11/1/21. (ntl)
Oct 27, 2021	10	Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for Bionpharma Inc. to answer, move or otherwise respond to the Complaint to 21 days after the Court rules on Bionpharma's Motion to Dismiss in C.A. No. 21-1286-LPS - filed by Bionpharma Inc.. (Phillips, John)
Oct 26, 2021	9	Main Document (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Andrew M. Alul & Roshan P. Shrestha - filed by Bionpharma Inc.. (Attachments: # (1) Certification of Andrew M. Alul, # (2) Certification of Roshan P. Shrestha)(Haney, Megan)
Oct 26, 2021	9	Certification of Andrew M. Alul (1)
Oct 26, 2021	9	Certification of Roshan P. Shrestha (1)
Oct 21, 2021	N/A	SO ORDERED (0) Docket Text: SO ORDERED, re [8] MOTION for Pro Hac Vice Appearance of Attorney Wendy L. Devine, Kristina M. Hanson, Nicholas Halkowski, Natalie J. Morgan, Evan Sumner, Ty W. Callahan and Granville C. Kaufman filed by Azurity Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 10/21/21. (ntl)
Oct 21, 2021	8	Motion for Leave to Appear Pro Hac Vice (9) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Wendy L. Devine, Kristina M. Hanson, Nicholas Halkowski, Natalie J. Morgan, Evan Sumner, Ty W. Callahan and Granville C. Kaufman - filed by Azurity Pharmaceuticals, Inc.. (Dellinger, Megan)
Oct 20, 2021	N/A	Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (nms)
Oct 15, 2021	1	Main Document (9) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT filed with Jury Demand against Bionpharma Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3721715.) - filed by Azurity Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(srs)
Oct 15, 2021	1	Exhibit A (28)
Oct 15, 2021	1	Civil Cover Sheet (2)
Oct 15, 2021	2	Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (srs)
Oct 15, 2021	3	ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date of Expiration of Patent: 03/25/2036. (srs)
Oct 15, 2021	4	Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,141,405 B2. (srs)
Oct 15, 2021	5	Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent CutisPharma Intermediate Holdings Inc. for Azurity Pharmaceuticals, Inc. filed by Azurity Pharmaceuticals, Inc.. (srs)
Oct 15, 2021	6	Summons Issued (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Bionpharma Inc. on 10/15/2021. (srs)
Oct 15, 2021	7	Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Azurity Pharmaceuticals, Inc.. Bionpharma Inc. served on 10/15/2021, answer due 11/5/2021. (Dellinger, Megan)
Oct 15, 2021	1	Complaint* (1)

Lawsuits

Azurity Pharmaceuticals, Inc. v. Bionpharma Inc. > Documents